Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasms 3Rectal Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pathologic Complete Response 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Liver Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 68Paclitaxel 32Radiotherapy 31Carboplatin 23Bevacizumab 21pembrolizumab 20Brachytherapy 18atezolizumab 11camrelizumab 10Nivolumab 10Gemcitabine 10Drug Therapy 9tislelizumab 8Topotecan 8Taxes 8Chemoradiotherapy 8Radiation 7Docetaxel 7Albumin-Bound Paclitaxel 7zimberelimab 6toripalimab 6nimotuzumab 6Magnetic Resonance Spectroscopy 6Cetuximab 6lenvatinib 5durvalumab 5dostarlimab 5Platinum 5Papillomavirus Vaccines 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uterine Cervical Neoplasms × veliparib × Clear all
NCT01266447 2019-08-08

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
27 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡